16 November 2023 - Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada.
GSK today announced that Health Canada has approved a new indication for Jemperli (dostarlimab for injection) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy, based on Part 1 of the pivotal RUBY study.